Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00101335
Other study ID # FCCC-02028
Secondary ID CDR0000393574
Status Completed
Phase Phase 2
First received January 7, 2005
Last updated July 9, 2013
Start date November 2003
Est. completion date January 2005

Study information

Verified date July 2013
Source Fox Chase Cancer Center
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of celecoxib may prevent or treat head and neck cancer.

PURPOSE: This randomized phase II trial is studying celecoxib to see how well it works compared to placebo in preventing head and neck cancer in patients with oral leukoplakia.


Description:

OBJECTIVES:

Primary

- Compare the clinical efficacy of celecoxib vs placebo, in terms of inducing regression of oral leukoplakia lesions, in patients with hyperplastic or dysplastic oral leukoplakia.

Secondary

- Determine the effect of this drug in modulating multiple intermediate biomarkers (e.g., COX-2, PPARĪ³, or PPARĪ“) in normal and hyperplastic or dysplastic oral epithelia of these patients.

- Determine the safety of this drug in these patients.

- Determine the cost-effectiveness of this drug as a chemopreventative agent in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled, cross-over study. Patients are stratified according to the pathology of the leukoplakia lesion (dysplasia vs hyperplasia). Patients are randomized to 1 of 2 arms.

- Arm I: Patients receive oral celecoxib twice daily for 3 months.

- Arm II: Patients receive oral placebo twice daily for 3 months. All patients undergo biopsy. Patients then cross-over to the opposite treatment arm for 3 months.

In both arms, treatment continues in the absence of unacceptable toxicity or disease progression.

Patients are followed at 1 month.

PROJECTED ACCRUAL: A total of 27-60 patients (18-40 for study drug, 9-20 for placebo before cross-over) will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date January 2005
Est. primary completion date January 2005
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Diagnosis of oral leukoplakia with hyperplasia or dysplasia

- Documented by baseline biopsy of oral lesions suspicious for leukoplakia

- For patients using dentures over the past 6 months, only lesions located on the ventral-lateral tongue or floor of the mouth are allowed

- No leukoplakia/hyperplasia secondary to mechanical irritation

- No carcinoma in situ of the oral cavity

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- Not specified

Life expectancy

- At least 1 year

Hematopoietic

- Hemoglobin = 10 g/dL (women) OR = 11 g/dL (men)

Hepatic

- AST or ALT normal

- Bilirubin normal

Renal

- Creatinine normal OR

- Creatinine clearance = 60 mL/min

Cardiovascular

- No myocardial infarction within the past 12 months

- No known active ischemic cardiac disease by stress test or echocardiogram

Gastrointestinal

- No history of gastrointestinal hemorrhage

- No known gastrointestinal ulcers within the past 2 years unless there is documentation of healed lesions by upper endoscopy

- No active or suspected peptic ulcer disease

- Negative stool guaiac test

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 2 months after study treatment

- No use of snuff or chewing tobacco within the past 2 months

- No active invasive malignancy within the past 3 years except nonmelanoma skin cancer or in situ carcinomas

- No clinical evidence of chronic infectious disease

- No clinical evidence of connective tissue disease

- No known hypersensitivity (asthma, urticaria, or acute rhinitis induced by NSAIDs) to aspirin or other NSAIDs

- No known hypersensitivity to sulfonamides

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- Not specified

Endocrine therapy

- At least 6 months since prior chronic or frequent use of systemic glucocorticoids

- No concurrent chronic or frequent use of systemic glucocorticoids

Radiotherapy

- Not specified

Surgery

- Not specified

Other

- No prior chronic or frequent (> 100 mg per day aspirin equivalent) use of nonsteroidal anti-inflammatory drugs (NSAIDs) for 7 of the past 14 days

- At least 3 months since prior experimental therapy

- No concurrent chronic or frequent use of NSAIDs

- Cardioprotective doses of aspirin = 100 mg daily are allowed

Study Design

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention


Intervention

Drug:
celecoxib


Locations

Country Name City State
United States Fox Chase Cancer Center Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Fox Chase Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Recruiting NCT05808920 - The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03997643 - Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT04700475 - Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients. N/A
Withdrawn NCT04058145 - AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma Phase 2
Completed NCT02572869 - Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Withdrawn NCT05073809 - Photoacoustic Imaging of Head and Neck Tumours
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Active, not recruiting NCT03651570 - Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study N/A
Recruiting NCT04930432 - Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors Phase 1/Phase 2
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Terminated NCT03843554 - Commensal Oral Microbiota in Head and Neck Cancer N/A
Recruiting NCT05915572 - Mulligan Technique on Shoulder Dysfunction N/A
Completed NCT05897983 - Tens and Rocabado Exercises on TMJ Dysfunction N/A
Not yet recruiting NCT06289049 - Heavy Strength Training in Head and Neck Cancer Survivors Phase 2
Withdrawn NCT05263648 - Virtual Reality Software to Reduce Stress in Cancer Patients N/A
Withdrawn NCT03238638 - A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy Phase 2